Xin Cui

Dr. Xin Cui


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in Stroke
Verified
Journal Article
Closed access
PDF file
YLYi Liu
Yi Liu
WWWeili Wang
Weili Wang
XCXin Cui
Xin Cui
JLJian Lyu
Jian Lyu
YXYanming Xie
Yanming Xie
BACKGROUND: Ischemic stroke (IS) is a major cause of disability and mortality worldwide. Increasing evidence suggests a strong association between blood pressure, blood glucose, circulating lipids, and IS. Nonetheless, the genetic association of these 3 risk factors with IS remains elusive. METHODS: We screened genetic instruments related to blood pressure, blood glucose, and circulating lipids and paired them with IS genome-wide association study data to conduct Mendelian randomization analysis. Positive Mendelian randomization findings were then subjected to colocalization analysis. Subsequently, we utilized the Gene Expression Omnibus data set to perform differential expression analysis, aiming to identify differentially expressed associated genes. We determined the importance scores of these differentially expressed associated genes through 4 machine learning models and constructed a nomogram based on these findings. RESULTS: The combined results of the Mendelian randomization analysis indicate that blood pressure (systolic blood pressure: odds ratio [OR], 1.02 [95% CI, 1.01–1.02]; diastolic blood pressure: OR, 1.03 [95% CI, 1.03–1.04]) and some circulating lipids (low-density lipoprotein cholesterol: OR, 1.06 [95% CI, 1.01–1.12]; apoA1: OR, 0.95 [95% CI, 0.92–0.98]; apoB: OR, 1.05 [95% CI, 1.01–1.09]; eicosapentaenoic acid: OR, 2.36 [95% CI, 1.41–3.96]) have causal relationships with the risk of IS onset. We identified 73 genes that are linked to blood pressure and circulating lipids in the context of IS, and 16 are differentially expressed associated genes. FURIN , MAN2A2 , HDDC3 , ALDH2 , and TOMM40 were identified as feature genes for constructing the nomogram that provides a quantitative prediction of the risk of IS onset. CONCLUSIONS: This study indicates that there are causal links between blood pressure, certain circulating lipids, and the development of IS. The potential mechanisms underlying these causal relationships involve the regulation of lipid metabolism, blood pressure, DNA repair and methylation, cell apoptosis and autophagy, immune inflammation, and neuronal protection, among others.

1 March 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
HGHongjiao Geng
Hongjiao Geng
LZLidan Zhang
Lidan Zhang
XCXin Cui
Xin Cui
CZCheng Zhang
Cheng Zhang
YXYanming Xie
Yanming Xie
Cerebral infarction is the second leading cause of death and the third most common cause of disability. The use of anti-platelet aggregation drugs is prone to bleeding, liver and kidney damage, gastrointestinal reactions, and is not suitable for patients to take for a long time. Xuesaitong oral preparations (XSTOP), a traditional Chinese medicine formula, has shown therapeutic effect on treating cerebral infarction based on the clinical practice and pharmacological mechanism. The study aims to evaluate the effectiveness and safety of XSTOP combined with conventional treatment (CT) in treatment of acute cerebral infarction (ACI), and to provide the reliable evidence for clinical application. We performed a literature search in Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, PubMed, EMBASE, Cochrane Library and Web of Science from their inceptions to August 2021. Systematic searches for randomized controlled trials (RCTs) of XSTOP in treatment of ACI. Odds ratio (OR) or mean difference (MD) with their 95% confidence interval was calculated between with and without XSTOP therapy. Cochrane risk of bias tool was used to evaluate the methodological quality of the included trials. Eight RCTs involving 827 patients were included in this meta-analysis. By comparing XSTOP plus conventional treatment with conventional treatment alone, the meta-analysis gave the following results: (1) Total effective rate (OR = 4.53, 95% CI[2.85, 7.19], P < 0.0001); (2) National Institutes of Health Stroke Scale (NIHSS) score (MD = -3.22, 95% CI[-4.52, -1.92], P<0.00001); (3) Plasma viscosity (PV) (MD = -0.74, 95%CI [-0.96, -0.51], P<0.00001), hole blood high-cut viscosity (HBV) (MD = -0.63, 95%CI [-0.73, -0.53], P = 0.84), whole blood low-cut viscosity (LBV) (MD = -0.37, 95%CI [-0.56, -0.19], P = 0.96), fibrinogen (FIB) (MD = -23.78, 95%CI [-28.57, -18.99], P = 1.00), hematocrit (Hct) (MD = -2.76, 95%CI [-3.16, -2.36], P = 0.96); (4) China Stroke Scale (CSS) score (MD = -6.53, 95% CI[-9.07, -3.99], P<0.00001); (5) No significant adverse reactions were reported; (6) The evidence was downgraded to "very low" quality, according to GRADE system. XSTOP plus CT is conditional recommended to improve the total effective rate, NIHSS score, PV, CSS score, and no serious adverse reactions were noted. The GRADE assessment indicates that the overall certainty quality of evidence is very low. Further large-scale, well-designed and high-quality RCTs are needed to confirm the positive results. As all studies included were conducted in China. It is unclear if the findings of this meta-analysis could be generalized to other populations.


4 June 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ZLZhenkai Lu
Zhenkai Lu
WFWenye Feng
Wenye Feng
YWYaxing Wang
Yaxing Wang
XZXuming Zhang
Xuming Zhang
XWXu Wei
Xu Wei
YXYanming Xie
Yanming Xie
Background: Postmenopausal osteoporosis (PMOP) and knee osteoarthritis (KOA) are common musculoskeletal disorders that share risk factors such as aging, hormonal changes, and inflammation. PMOP often remains asymptomatic until fractures occur, while KOA leads to pain and disability. Their comorbidity remains underexplored, particularly in community settings. This study aims to investigate the prevalence, risk factors, and clinical features of PMOP-KOA comorbidity among Beijing residents aged 45–80 years, providing evidence-based recommendations for early identification, prevention, and management.Methods: Over 2 years, this study will conduct a PMOP-KOA screening and prospective follow-up in the Beijing community to investigate the incidence, risk factors, and clinical characteristics of PMOP-KOA. This study will undertake bone mineral density detection, collect biological samples, and record information via questionnaires.Discussion: The study aims to investigate the incidence, risk factors, and clinical characteristics of PMOP-KOA comorbidity and explore related traditional Chinese medicine syndromes based on large community-based samples in Beijing. Data on PMOP-KOA occurrence and associated risk factors over the 2 years follow-up will be available on the Chinese Clinical Trial Registry (ChiCTR2300073575).


21 March 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
MWMengmeng Wang
Mengmeng Wang
LWLianxin Wang
Lianxin Wang
FLFumei Liu
Fumei Liu
RCRenbo Chen
Renbo Chen
ZWZhifei Wang
Zhifei Wang
YXYanming Xie
Yanming Xie
Background: Pudilan Xiaoyan oral liquid (PDL) is a proprietary Chinese medicine preparation widely used for upper respiratory tract infection, known for its significant therapeutic effects. However, the safety profiles reported in several observational studies vary, and these studies primarily focus on efficacy rather than specifically addressing safety concerns, thus representing inadequate safety monitoring. Objective: This study aimed to investigate the incidence of adverse drug reactions (ADRs) associated with PDL and explore the factors contributing to these reactions. Methods: The study is a prospective, observational, multicenter, hospital-based surveillance study. A total of 17 hospitals from China are involved. The study is expected to enroll a large sample of 10,000 patients aged between 18 and 80 years with upper respiratory tract infection who were prescribed PDL. The patients’ data, including demographics, medical history, diagnostic information, medication details, adverse events, and laboratory test results, will be monitored. The occurrence of ADRs will be recorded. The primary outcome is the incidence of ADR. Secondary outcomes are the ratio of patients whose body temperature return to the normal range (cases of body temperature normalization and the duration for achieving normal body temperature within a 3-day period will be documented) and changes in liver and kidney function (occurrence of drug-induced liver injury and acute kidney injury). Descriptive analyses will be performed for the primary and secondary outcomes. A cohort, nested, case-control study design will be used. If one patient has an ADR, then 4 patients without ADRs will be matched as the control group according to gender, age within 5 years, drug batch, and other factors, at a ratio of 1∶4 to compare the symptoms related to ADRs. The differences of ADR incidence among the possible influencing factors will be compared separately to find the factors with large differences. Then, synthetic minority oversampling technique and group least absolute shrinkage and selection operator methods will be used to identify factors influencing the occurrence of ADRs. Finally, propensity scoring methods will be used to control for confounding variables. The progress of each subcenter will be closely monitored, and the incidence of ADR will be systematically calculated. Furthermore, the characteristics and influencing factors of ADR will be analyzed, along with an investigation into its geographical distribution. Results: The study began on July 17, 2019. Due to the limited number of eligible patients, missed follow-ups, and the huge clinical burden caused by public health events in 2019, the final case will be enrolled on August 30, 2025. Conclusions: This study will obtain safety results of PDL in the real world and provide guidance on the clinical safety of traditional Chinese medicine formulations. Trial Registration: ClinicalTrials.gov NCT04031651; https://clinicaltrials.gov/study/NCT04031651 International Registered Report Identifier (IRRID): DERR1-10.2196/65789